About this Research Topic
Breast cancer is one of the most common cancers in the world. Despite the better outcomes after the improvement of specific therapies, a significant number of patients undergo metastasis or drug/endocrine resistance which leads to poor survival of the patients. Hence, exploring the novel vulnerabilities targeting the plastic nature of the cancers would be critical in developing better therapeutic targets. Transcriptional regulation and epigenetic mechanisms should be explored in this case, as they have great potential to be targeted specifically using small molecule inhibitors given the emergence in clinical trials testing them in solid tumors.
The major issue we face in treating breast cancer patients is drug resistance or metastasis which leads to aggressive disease. There are currently no specific treatments available to treat metastatic patients. However, recent advances in developing epigenetic inhibitors have promised specific targeting of cellular processes including metastasis. Identifying the reprogrammed epigenetic modifications or proteins have more potential benefits in personalized and targeted medicine.
We would like to invite articles that decipher how epigenetic reprogramming can play a role in cancer progression and/or that explore epigenetic targeting approaches to improve the survival of breast cancer patients, especially in advanced stages. This can include investigating the mechanisms of action of transcription factors, epigenetic and chromatin-associated marks, or proteins via genomics, proteomics, epigenomics, transcriptomics, etc., or at a gene-specific/focused level. Particular emphasis is needed on how advanced diseases can be modulated by studying the function of the epigenetic aspects in vitro/in vivo using physiologically relevant models. Various article types are welcome.
Descriptive studies consisting solely of bioinformatic investigation of publicly available genomic/transcriptomic/proteomic data do not fall within the scope of the section unless they are expanded and provide significant biological or mechanistic insight into the process being studied.
The major issue we face in treating breast cancer patients is drug resistance or metastasis which leads to aggressive disease. There are currently no specific treatments available to treat metastatic patients. However, recent advances in developing epigenetic inhibitors have promised specific targeting of cellular processes including metastasis. Identifying the reprogrammed epigenetic modifications or proteins have more potential benefits in personalized and targeted medicine.
We would like to invite articles that decipher how epigenetic reprogramming can play a role in cancer progression and/or that explore epigenetic targeting approaches to improve the survival of breast cancer patients, especially in advanced stages. This can include investigating the mechanisms of action of transcription factors, epigenetic and chromatin-associated marks, or proteins via genomics, proteomics, epigenomics, transcriptomics, etc., or at a gene-specific/focused level. Particular emphasis is needed on how advanced diseases can be modulated by studying the function of the epigenetic aspects in vitro/in vivo using physiologically relevant models. Various article types are welcome.
Descriptive studies consisting solely of bioinformatic investigation of publicly available genomic/transcriptomic/proteomic data do not fall within the scope of the section unless they are expanded and provide significant biological or mechanistic insight into the process being studied.
Keywords: epigenetic proteins, breast cancer, drug resistance, metastasis
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
